Search Results
Your search for all items matches 503 pages
Showing 51 - 100
Paolo A. Ascierto, MD, on Melanoma: Results From CheckMate 238 on Adjuvant Nivolumab vs Ipilimumab
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, Napoli, discusses phase III study findings confirming the superior activity of nivolumab vs ipilimumab in resected stage III/IV melanoma in terms of regression-free survival after a minimum follow-up of 36 months (Abstract 1310O).
Genomic Landscape of Merkel Cell Carcinoma
Researchers have developed the largest descriptive genomic analysis of patients with Merkel cell carcinoma to date. Their analysis, published by Knepper et al in Clinical Cancer Research, will provide important information to improve the care and treatment of patients with Merkel cell...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Risk of Cardiovascular Adverse Events in Patients With Melanoma Treated With Combined BRAF and MEK Inhibition vs BRAF Inhibition Alone
In a meta-analysis reported in JAMA Network Open, Mincu et al found that the risk of some types of cardiovascular adverse events was higher with combined BRAF and MEK inhibitor treatment vs BRAF inhibitor monotherapy in patients with melanoma. The meta-analysis included 2,317 patients in five...
Can Genetic Counseling and Test Reporting in Patients Susceptible to Melanoma Development Change Behavior?
A new study published by Stump et al in Genetics in Medicine investigated whether genetic testing would motivate people at risk of developing melanoma to alter their behavior in order to reduce their risk. “We are trying to understand whether a genetic test result adds value over and above...
Is Vitamin A Intake Linked to Cutaneous Squamous Cell Carcinoma Risk?
People whose diets included high levels of vitamin A had a 17% reduction in risk for developing cutaneous squamous cell carcinoma, as compared to those who ate modest amounts of foods and supplements rich in vitamin A. These findings were published by Kim et al in JAMA Dermatology. Vitamin A is...
FDA Pipeline: Breakthrough Therapy for Melanoma, Investigational New Drug for Advanced Solid Tumors
This week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bempegaldesleukin in combination with nivolumab for advanced melanoma and cleared an investigational new drug application for a phase I trial of SB 11285 in advanced solid tumors. Breakthrough...
Post Hoc 5-Year Follow-up of Pembrolizumab vs Ipilimumab in Advanced Melanoma
In a post hoc 5-year follow-up of the KEYNOTE-006 trial reported in The Lancet Oncology, Robert et al found that pembrolizumab maintained overall and progression-free survival benefits over ipilimumab in patients with advanced melanoma. In the primary analysis from the trial, both pembrolizumab...
Survey Finds Majority of Americans Are Unfamiliar With Cutaneous Squamous Cell Carcinoma
Nearly-three quarters of Americans are not familiar with cutaneous squamous cell carcinoma, the second most common type of cancer in the United States, according to a new survey conducted by The Harris Poll on behalf of The Skin Cancer Foundation. Cutaneous squamous cell carcinoma is more common...
Five-Year Survival in Heavily Pretreated Patients Receiving Nivolumab Monotherapy
As reported by Topalian et al in JAMA Oncology, long-term follow up of patients from a phase I expansion cohort study indicated 5-year overall survival rates of 34.2%, 27.7%, and 15.6% among patients who received nivolumab monotherapy for advanced melanoma, renal cell carcinoma (RCC), and...
Family History of Melanoma May Increase Risk for Nonmelanoma Skin Cancers
A study by Wei et al in the Journal of the American Academy of Dermatology has found that individuals with a first-degree relative with a history of melanoma are at an increased risk for melanomas and keratinocyte cancers such as squamous cell carcinoma and basal cell carcinoma. Methods...
Upgrading of Nonmelanoma Skin Cancers at the Time of Mohs Surgery
Nonmelanoma skin cancers may display an aggressive histologic subtype that is not diagnosed on initial biopsy. In a prospective, cross-sectional study reported by Kyllo et al in the Journal of the American Academy of Dermatology, researchers determined that a significant portion of nomelanoma...
Does Size of Surgical Excision Margins for Thick Localized Cutaneous Melanoma Affect Survival Outcomes?
In a nearly 20-year follow-up of a Scandinavian trial reported in The Lancet, Utjés et al found no difference in survival outcomes with 2-cm vs 4-cm surgical excision margins for primary localized cutaneous melanoma with a thickness > 2 mm. The previous report from the trial showed no...
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
Anti-KIR3DL2 Monoclonal Antibody for Relapsed or Refractory Cutaneous T-Cell Lymphoma
In a phase I trial reported in The Lancet Oncology, Bagot et al found that IPH4102—a first-in-class monoclonal antibody targeting KIR3DL2—was safe and showed activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome....
ECHO-301/KEYNOTE-252: Addition of Epacadostat to Pembrolizumab in Unresectable or Metastatic Melanoma
As reported in The Lancet Oncology by Long et al, the phase III ECHO-301/KEYNOTE-252 trial showed no improvement in progression-free or overall survival with the addition of the IDO1 inhibitor epacadostat to pembrolizumab in unresectable stage III or stage IV melanoma. Study Details In the...
15-ICML: Final Data From ALCANZA: Brentuximab Vedotin for CD30-Positive CTCL
Final analyses from the ALCANZA study, a phase III trial investigating brentuximab vedotin vs physician’s choice for the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL), were presented by Horwitz et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract...
Comparison of Combination Dosing Schedules of Neoadjuvant Ipilimumab/Nivolumab in Macroscopic Stage III Melanoma
In the phase II OpACIN-neo study reported in The Lancet Oncology, Rozeman et al identified a promising dosing schedule for neoadjuvant ipilimumab/nivolumab in macroscopic stage III melanoma. Study Design The trial included 86 evaluable patients with resectable stage III melanoma involving the...
Performance of Machine-Learning Classifiers in the Diagnosis of Pigmented Skin Lesions
In a study conducted under the supervision of researchers from the MedUni Vienna, human experts competed against computer algorithms in diagnosing pigmented skin lesions. The algorithms achieved better results when diagnosing, but had decreased performance for out-of-distribution images. These...
Neoadjuvant Dabrafenib/Trametinib in Stage IIIB/C, BRAF V600–Mutant Melanoma
In the single-center, phase II NeoCombi trial reported in The Lancet Oncology, Long et al found that neoadjuvant dabrafenib plus trametinib produced promising response rates in resectable, stage IIIB/C, BRAF V600–mutant melanoma. As noted by the investigators, adjuvant dabrafenib plus...
2019 ASCO: OPTiM Study on T-VEC for Unresectable Melanoma
New research on the immunotherapy talimogene laherparepvec (T-VEC)—an injectable oncolytic virus—for patients with unresectable melanoma was presented by Milhem et al at the 2019 ASCO Annual Meeting (Abstract 9524). Researchers reported the ad hoc analysis of progression-free survival...
2019 ASCO: Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma
In an extended analysis of the COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting (Abstract 9507) and in The New England Journal of Medicine, Robert et al found a 5-year overall survival rate of 34% with the combination of dabrafenib and trametinib in previously untreated...
Ahmad A. Tarhini, MD, PhD, on High-Risk Melanoma: Adjuvant Ipilimumab vs High-Dose Interferon-α2b
Ahmad A. Tarhini, MD, PhD, of Emory University and Winship Cancer Institute, discusses phase III findings from the U.S. Intergroup E1609 trial, which showed survival benefits for patients with resected high-risk melanoma—for the first time in the history of melanoma adjuvant therapy (Abstract...
Predicting Response to Immunotherapy in Squamous Cell Carcinoma
According to a study published by Kacew et al in the European Journal of Cancer, copy number alterations in the chromosome 3q arm may be linked to immunotherapy response in patients with cutaneous squamous cell carcinoma. In fact, this and other genetic markers may prove to be useful...
Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers
Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...
Link Between Skin Cancer Diagnosis and Health-Care Screening Practices
According to findings published by Drucker et al in JAMA Dermatology, patients undergoing health-care screening practices for skin cancer have a higher likelihood of being diagnosed—particularly for squamous cell and basal cell carcinomas—than those who do not. Researchers...
PD-1 Inhibitor–Associated Cutaneous Toxicity and Clinical Outcomes in Advanced Melanoma
In a research letter published in JAMA Oncology, Quach et al found that cutaneous toxicities related to anti–programmed cell death protein 1 (PD-1) treatment—specifically, vitiligo and rash—were associated with improved clinical outcomes in advanced melanoma. Study Details The...
Does Squamous Cell Carcinoma Risk Change With Immunosuppression?
Immunosuppressed patients seem to have an increased risk of poor outcomes with multiple squamous cell carcinomas compared with those who are immunocompetent. Jessica L. Gonzalez, MD, of Tufts Medical Center in Boston, and colleagues published the results of a single-center case-control study...
Does Intake of Dietary Fat Increase Risk of Skin Cancer?
Dietary intake of fat is associated with several types of cancer, but few studies have explored the link between fat intake and the risk of skin cancer. In a study published by Park et al in Cancer Epidemiology, Biomarkers & Prevention, researchers examined the relationship between fat intake...
FDA Pipeline: Designation in Uveal Melanoma, Application for MDS Side-Effect Management
Over the past week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for metastatic uveal melanoma and received a biologics application for an agent to control anemia. Fast Track Designation for Tebentafusp in Metastatic Uveal Melanoma The FDA granted...
Skin Cancer 2019: Recurrence and Staging of Cutaneous Squamous Cell Carcinoma After Mohs Surgery
Mohs surgery is known to have lower recurrence rate compared to conventional wide excision for removal of cutaneous squamous cell carcinomas. However, cutaneous squamous cell carcinoma does sometimes recur—even after Mohs surgery. In a Korean study by Roh et al presented at the World Congress ...
Skin Cancer 2019: Small Study of Electrochemotherapy for Basal Cell Carcinomas in the Head and Neck Region
Increasing evidence is emerging about the effectiveness of electrochemotherapy in the treatment of basal cell carcinomas in the head and neck region. A study presented by Kis et al at the World Congress on Advanced Treatments and Technologies in Skin Cancer (Skin Cancer 2019) (Poster Board 6) aimed ...
Skin Cancer 2019: Reflectance Confocal Microscopy Plus Optical Coherence Tomography in Diagnosing Suspicious Basal Cell Carcinoma Lesions
The increasing incidence and prevalence of nonmelanoma skin cancers has led to the search for new and more efficient diagnostic imaging and therapy guidance approaches. However, proper selection of therapy requires the precise delineation of skin cancer margins. To address this need, researchers...
Patient-Reported Outcomes in the COMBI-AD Trial
In a study focused on the phase III COMBI-AD trial reported in The Lancet Oncology, Schadendorf et al found no difference in patient-reported outcomes with adjuvant dabrafenib plus trametinib vs placebo in patients with resected BRAF V600E– or BRAF V600K–mutant stage III melanoma. The...
AACR 2019: Entinostat Plus Pembrolizumab in Patients With Melanoma Previously Treated With Anti–PD-1 Therapy
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed clinical responses in patients with melanoma that had progressed on prior anti–PD-1 treatment, according to results from the phase...
Characteristics and Prognosis Associated With Thin Nodular Primary Melanomas
In a study reported in the Journal of the National Cancer Institute, Dessinioti et al found that thin nodular primary melanomas are associated with aggressive characteristics that may portend poorer prognosis vs superficial spreading melanomas. Study Details The study involved data on 5,062...
Keratinocyte Carcinoma: Update on Treatment and Prevention
Keratinocyte carcinoma, previously known as nonmelanoma skin cancer, is the most common malignancy in fair-skinned populations worldwide. In a review article published in Current Opinion in Pharmacology, Alexander Zink, MD, MPH, PhD, of the Technical University of Munich, proposed that...
Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice
Chrysalyne Schmults, MD, of Brigham and Women’s Hospital, discusses treatment strategies in these nonmelanoma skin cancers, including surgery, forthcoming staging systems, and ongoing trials combining adjuvant radiotherapy and immunotherapy.
Immunotherapy Directed Against Precancerous Skin Lesions May Prevent Squamous Cell Carcinoma
A treatment previously shown to treat the precancerous skin lesions called actinic keratosis now appears to also reduce the chance that these pretreated lesions will develop into squamous cell carcinoma. In a report published by Rosenberg et al in JCI Insight, researchers found that treatment with...
Incidence of Nonmelanoma Skin Cancer in Recipients of Multiple Kidney Transplants
The incidence of nonmelanoma skin cancer may be more common in recipients of kidney transplants vs patients on maintenance dialysis. Researchers looked to determine if the risk of nonmelanoma skin cancer is lower during periods of graft loss with a return to dialysis vs during periods of...
What Is the Best Field-Directed Treatment for Actinic Keratosis?
In a Dutch study reported in The New England Journal of Medicine, Jansen et al found that 5% fluorouracil cream was the best of four field-directed treatments for actinic keratosis, the most common premalignant skin disease in the white population. Study Details The study examined the...
Safety Comparison of Two Dosing Regimens for Nivolumab Plus Ipilimumab in Advanced Melanoma
In the phase IIIb/IV CheckMate 511 study reported by Lebbé et al in the Journal of Clinical Oncology, a regimen of nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg (NIVO3+IPI1) was found to significantly reduce the incidence of treatment-related grade 3 to 5 adverse events compared with...
New Patient Resource: NCCN Guidelines for Patients With Squamous Cell Skin Cancer
The National Comprehensive Cancer Network® (NCCN) has published a new book of patient information that explains prevention, diagnosis, and treatment for squamous cell skin cancer. Squamous cell and basal cell skin cancers are responsible for about 5 million annual incidents of nonmelanoma...
Is the Presence of Nevi on Extremities a Risk Factor for Melanoma and Nonmelanoma Skin Cancers?
The presence of nevi is an established risk factor for melanoma. In light of this, researchers examined the association between the presence of nevi on extremities and the risk of melanoma and nonmelanoma skin cancers. Their findings were published by Wei et al in the Journal of the American...
A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma
A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be...
2019 AAD: Disadvantages and Potential Improvements of Artificial Intelligence in Skin Cancer Detection
While artificial intelligence (AI) systems for skin cancer detection have shown promise in research settings, there is still a lot of work to be done before the technology is appropriate for real-world use. This was the topic of a scientific session at the 2019 American Academy of Dermatology (AAD) ...
AACR 2019: Diet May Influence Gut Microbiome and Response to Immunotherapy
Among patients with melanoma treated with anti–programmed cell death protein 1 (PD-1) immunotherapy, consumption of a high-fiber diet was associated with higher gut microbiome diversity and better response to treatment, according to data presented by Spencer et al at a presscast in advance of ...
Cutaneous T-Cell Lymphoma: Can Genetic Polymorphisms Help Select Patients for Treatment With Bexarotene?
Bexarotene is a retinoid approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have not responded to at least one previous treatment regimen. Hypertrigylceridemia is the most frequent adverse event related to treatment with bexarotene in CTCL. Even with prophylactic...
FDA Approves Adjuvant Pembrolizumab for Melanoma
On February 15, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with melanoma with lymph node involvement following complete resection. Approval was based on the phase III EORTC1325/KEYNOTE-054 trial, a randomized, double-blind,...
First-Line Pembrolizumab in Advanced Merkel Cell Carcinoma
In a phase II trial (Cancer Immunotherapy Trials Network-09/Keynote-017) reported in the Journal of Clinical Oncology, Nghiem et al found that first-line pembrolizumab produced a high response rate in patients with advanced Merkel cell carcinoma. In the multicenter trial, 50 adult patients who had ...
